Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study

Psychiatry and Clinical Neurosciences

Volumn 72, Issue 9, 2018, Pages 692-700

  Ishigooka, Jun ^a   Iwashita, Shuichi ^b   Tadori, Yoshihiro ^b  

^a CNS Pharmacological Research Institute   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

brexpiprazole; efficacy; Japanese; safety; schizophrenia

Indexed keywords

BREXPIPRAZOLE; PLACEBO; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; AKATHISIA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DENTAL CARIES; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; TREATMENT DURATION; VOMITING; ADOLESCENT; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; QUINOLONES; SCHIZOPHRENIA; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85050600677     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12682     Document Type: Article

References (14)

1. Lewis DA, Lieberman JA. Catching up on schizophrenia: Natural history and neurobiology. Neuron 2000; 28: 325–334.
2. Correll CU. From receptor pharmacology to improved outcomes: Individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry 2010; 25 (Suppl. 2): S12–S21.
3. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 2013; 382: 951–962.
4. Bruijnzeel D, Tandon R. Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression. Drug Des. Devel. Ther. 2016; 10: 1641–1647.
5. Maeda K, Sugino H, Akazawa H et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J. Pharmacol. Exp. Ther. 2014; 350: 589–604.
6. Kane JM, Skuban A, Ouyang J et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr. Res. 2015; 164: 127–135.
7. Correll CU, Skuban A, Ouyang J et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry 2015; 172: 870–880.
8. Correll CU, Skuban A, Hobart M et al. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. Schizophr. Res. 2016; 174: 82–92.
9. Kane JM, Skuban A, Hobart M et al. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr. Res. 2016; 174: 93–98.
10. Ishigooka J, Iwashita S, Higashi K, Liew EL, Tadori Y. Pharmacokinetics and safety of brexpiprazole, following multiple-dose administration to Japanese patients with schizophrenia. J. Clin. Pharmacol. 2018; 58: 74–80.
11. Ishigooka J, Iwashita S, Tadori Y. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study. Psychiatry Clin. Neurosci. 2018; 72: 445–453.
12. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J. Clin. Psychiatry 1997; 58: 538–546.
13. Kong L, Koch G, Liu T, Wang H. Performance of some multiple testing procedures to compare three doses of a test drug and placebo. Pharm. Stat. 2005; 4: 25–35.
14. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov AIII, Assunção-Talbott S. Akathisia: An updated review focusing on second-generation antipsychotics. J. Clin. Psychiatry 2009; 70: 627–643.